5-Hydroxymethyl-1-methyl-3-phenyl-1,2,4-triazol | 26254-08-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Hydroxymethyl-1-methyl-3-phenyl-1,2,4-triazol
• 英文别名: (2-methyl-5-phenyl-2H-[1,2,4]triazol-3-yl)-methanol；(1-methyl-3-phenyl-1H-1,2,4-triazol-5-yl)methanol；(2-methyl-5-phenyl-1,2,4-triazol-3-yl)methanol
• CAS: 26254-08-0
• 化学式: C₁₀H₁₁N₃O
• 分子量: 189.217
• InChiKey: PBLQPTDTINPFBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Hydroxymethyl-1-methyl-3-phenyl-1,2,4-triazol 在 lead(IV) acetate 作用下， 以 乙醇 、 苯 为溶剂， 反应 6.0h， 生成 4-Dimethylamino-N-<(1-methyl-3-phenyl-1,2,4-triazol-5-yl)methylen>anilin
  参考文献：
  名称：

  Moderhack, Dietrich, Liebigs Annalen der Chemie, 1984, # 1, p. 48 - 65

  摘要：

  DOI：
• 作为产物：
  描述：

  2-苯基-2-恶唑啉-4-酮 、 甲基肼 以 乙醇 为溶剂， 反应 1.0h， 生成 5-Hydroxymethyl-1-methyl-3-phenyl-1,2,4-triazol
  参考文献：
  名称：

  [EN] HETEROAROMATIC ARYL TRIAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
  [FR] DÉRIVÉS HÉTÉROAROMATIQUES D'ARYLTRIAZOLE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A

  摘要：

  这项发明涉及化合物（式1），其为PDE10A酶抑制剂。该发明提供了一种包括本发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式（I）化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用化合物式（I）的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者施用化合物式（I）的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用化合物式（I）的治疗有效量。

  公开号：

  WO2011072697A1

文献信息

• [EN] (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] (HÉTÉRO)ARYL IMIDAZOLES/PYRAZOLES POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015113980A1

  公开（公告）日：2015-08-06

  The present invention relates to compounds of formula (I), wherein A and B, X, Y, Z, and R1-R6 are as defined in the claims, for the treatment of neurological disorders.

  本发明涉及式(I)的化合物，其中A和B，X，Y，Z，以及R1-R6如权利要求中所定义的，用于治疗神经系统疾病。
• [EN] HETEROAROMATIC ARYL TRIAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROAROMATIQUES D'ARYLTRIAZOLE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2011072697A1

  公开（公告）日：2011-06-23

  This invention is directed to compounds (Formula 1), which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  这项发明涉及化合物（式1），其为PDE10A酶抑制剂。该发明提供了一种包括本发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式（I）化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用化合物式（I）的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者施用化合物式（I）的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用化合物式（I）的治疗有效量。
• Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors
  申请人：Püschl Ask

  公开号：US20120309764A1

  公开（公告）日：2012-12-06

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及一种PDE10A酶抑制剂化合物。本发明提供一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法，包括向患者施用式I化合物的治疗有效量。
• Heteroaromatic Aryl Triazole Derivatives as PDE10A Enzyme Inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20130281459A1

  公开（公告）日：2013-10-24

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  本发明涉及一种PDE10A酶抑制剂化合物。本发明提供了一种制药组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法，包括向患者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法，包括向患者施用式I化合物的治疗有效量。
• (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders
  申请人：Hoffmann-La Roche Inc.

  公开号：US10399985B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.

  本发明涉及式 I 的化合物，其中 A、B、R1、R2 和 Z 如前定义。